GlassScriptPhysician profile
Tushar Thakur
NPI 1467829275
$2,059.09
in general payments reported to CMS, 2019-2025
20 companies · $784 in 2025
The $784 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.06 · 2022: $227 · 2023: $320 · 2024: $714 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,818.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $322.69 | 2022-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $283.86 | 2022-2024 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $269.19 | 2024 | Acthar, Terlivaz |
| Otsuka America Pharmaceutical, INC. | $229.39 | 2022-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $200.47 | 2022-2025 | |
| Lilly USA, LLC | $138.14 | 2025 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $120.90 | 2025 | |
| Ardelyx, INC. | $106.67 | 2024 | Xphozah 30 Mg |
| Amgen INC. | $87.16 | 2022-2025 | Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $48.18 | 2023-2025 | Livtencity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.37 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $32.92 | 2023 | Benlysta, Jesduvroq |
| Vifor Pharma, INC. | $29.76 | 2023 | Veltassa, Korsuva |
| Aurinia Pharma U.S., INC. | $27.88 | 2022 | |
| Akebia Therapeutics INC | $27.53 | 2025 | Vafseo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $21.51 | 2025 | Rybelsus, Ozempic |
| Alexion Pharmaceuticals, INC. | $20.56 | 2023 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $19.60 | 2025 | |
| Opko Pharmaceuticals, LLC | $19.25 | 2024 | Rayaldee |
| Janssen Pharmaceuticals, INC | $13.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tushar Thakur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.